Allelic deletions on human chromosome 12q24 are frequently reported in a variety of malignant neoplasms, indicating the presence of a tumor suppressor gene(s) in this chromosomal region. However, no reasonable candidate has been identified so far. In this study, we report the cloning and functional characterization of a novel mitochondrial protein with tumor suppressor activity, henceforth designated MITOSTATIN. Human MITOS-TATIN was found within a 3.2-kb transcript, which encoded a B62 kDa, ubiquitously expressed protein with little homology to any known protein. We found homozygous deletions and mutations of MITOSTATIN gene in B5 and B11% of various cancer-derived cells and solid tumors, respectively. When transiently overexpressed, MITOSTATIN inhibited colony formation, tumor cell growth and was proapoptotic, all features shared by established tumor suppressor genes. We discovered a specific link between MITOSTATIN overexpression and downregulation of Hsp27. Conversely, MITOSTATIN knockdown cells showed an increase in cell growth and cell survival rates. Finally, MITOSTATIN expression was significantly reduced in primary bladder and breast tumors, and its reduction was associated with advanced tumor stages. Our findings support the hypothesis that MITOSTATIN has many hallmarks of a classical tumor suppressor in solid tumors and may play an important role in cancer development and progression.
Introduction
During the course of cancer development, a normal cell progresses towards malignancy by acquiring a specific series of mutations (Hanahan and Weinberg, 2000) . Over the past decades, genetic studies have demonstrated that cancer cells accumulate DNA changes that activate oncogenes and inactivate tumor suppressor genes. The role of tumor suppressor genes in neoplastic development is crucial, given that reintroduction of one or more of these genes into cells in which their function is compromised can completely revert the neoplastic phenotype. Therefore, it is not surprising that several tumors show a high frequency of loss of heterozygosity (LOH) at specific chromosomal regions encompassing tumor suppressor genes. LOH in the telomeric regions of chromosome 12 has been observed in many solid tumors, such as breast (Tirkkonen et al., 1997; Aubele et al., 2000) , lung (Shiseki et al., 1996) , gastric, and prostate cancers (Schmutte et al., 1997; Sattler et al., 1999) , pancreatic adenocarcinoma (Kimura et al., 1998) , head and neck squamous cell carcinoma (Field et al., 1995) , distal bile duct carcinoma (Rijken et al., 1999) , renal cell carcinomas (Jiang et al., 1998) and urothelial carcinoma of the urinary bladder (Koo et al., 1999) . These observations support the concept that cloning and characterization of tumor suppressor genes may lead to the development of novel therapies for malignant tumors.
In the process of screening for genes expressed during growth arrest induced by the small leucine-rich proteoglycan decorin (Santra et al., 1995 (Santra et al., , 1997 Moscatello et al., 1998; Csordas et al., 2000; Xu et al., 2002; Goldoni et al., 2007) , we identified an expressedsequence-tag that was upregulated in three different growth-suppressed tumor cell lines (that is, decorintransfected tumor cells). We investigated in more detail the nature of one of these expressed-sequence-tags for several reasons. First, its key chromosomal location is a known fragile site in cancer. Second, the overexpression of this gene product was induced by decorin, a growthinhibitory protein (Santra et al., 1997; Goldoni et al., 2007) . Third, it is well established that the regulatory effect on cell growth may be mediated by variations on the level of expression of downstream genes through a paracrine or autocrine mechanism.
In this study, we described the cloning of a novel putative tumor suppressor gene (previously identified as Ts12q for tumor suppressor at 12q) and named it MITOSTATIN, for mitochondrial protein with oncostatic activity. Our genetic and functional studies support a potential key role for MITOSTATIN in the development and progression of cancer.
Results
Cloning and characterization of MITOSTATIN Using differential hybridization of cDNA libraries (subtractive hybridization) with probes obtained from logarithmically growing or growth-suppressed cells (that is, decorin-transfected tumor cells), we isolated different growth-regulated genes. Northern blot of one of these novel transcripts showed a 10-fold induction in three different decorin-transfected cells (A431, HeLa and HT1080 cells), recognizing a transcript of B3.2 kb (data not shown). The difference in the MITOSTATIN protein levels between the clone and the parental line was confirmed by immunoblotting analysis (Supplementary Figure S1 ). At the time of the cloning, homology searches against expressed-sequence-tag databases showed complete identity with a published human expressed-sequence-tag. Human testis and skeletal muscle cDNA libraries were screened and 3 0 /5 0 RACE PCR was performed to clone the 3.2-kb full-length cDNA, including a 1497 bp open reading frame containing a starting ATG codon at position 216 within a perfect Kozak consensus sequence that we called MITOSTATIN (deposited in the GeneBank with accession number AY007230). The entire human MITOSTATIN spans 17 kb of genomic DNA, with 13 exons, 12 of which were coding exons ( Figure 1a ). Search analysis against available protein databases identified Pan troglodytes, Pongo Pygmaeus, Canis familiaris, Bos Taurus, Mus musculus and Rattus norvegicus proteins with high homology (>80%) with the MITOSTATIN ORF, indicating that it is highly conserved in mammals (Figure 1b and Supplementary Figure S2 ).
Expression of human MITOSTATIN MITOSTATIN expression in normal human tissues was examined using two multiple normal-tissue northern blots. All tissues examined (brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung, peripheral blood leukocyte, prostate, testis and ovary) demonstrated the presence of the 3.2 kb MITOSTATIN transcript, albeit at different levels. The highest RNA expression was detected in heart, skeletal muscle, kidney, liver and testis. A larger 5.5 kb transcript was observed in heart and skeletal muscle. A smaller RNA transcript of 1.24 kb was also detected in heart mRNA ( Figure 1c) .
To determine whether the wild-type MITOSTATIN cDNA could be translated in vitro, we performed in vitro transcription/translation by a TnT-coupled reticulocyte system. Analysis of the synthesized protein by SDS-polyacrylamide gel electrophoresis and autoradiography confirmed the 61.2 kDa predicted protein (Supplementary Figure S4) . To assess whether MITOS-TATIN cDNA could be translated in vivo, full-length MITOSTATIN was cloned in pcDNA3.1 Myc/His vector. Western blot analysis of the fusion protein in HeLa and 293T transfected cells showed presence of the MITOSTATIN protein around 62 kDa. 
¼ peripheral blood leukocyte, 13 ¼ prostate, 14 ¼ testis and 15 ¼ ovary). The b-actin RNA was used as control.
Next, we determined the subcellular localization of this newly identified gene product to gain insights into its function. Various expression vectors harboring MITOSTATIN with green fluorescent protein (GFP) located at the N-or C-terminal ends, or with FLAG epitopes at the C terminus were generated and tested in transient cell transfection assays in HeLa cells. In all cases, MITOSTATIN exhibited punctuate vesicular distribution throughout the cytoplasm (Figure 2a) . Next, we discovered that MITOSTATIN colocalized with mitochondrial markers (Figure 2b ). To corroborate this subcellular distribution, we used subcellular fractionation and immunoblotting of the various fractions. The results showed that MITOSTATIN specifically sedimented in the heavy mitochondrial fraction together with cytochrome c (Figure 2c ). Similar results were obtained in embryonic kidney 293T cells and prostate cancer-derived cell lines PC3 and LNCaP (Supplementary Figure S5 ). We did not detect any colocalization of MITOSTATIN with lysosomes, Golgi apparatus or endosomal compartment (Supplementary Figure S6) . These results clearly show that MITOSTATIN is a novel mitochondria-associated protein.
MITOSTATIN interferes on mitochondria morphology and ultrastructural organization As confocal images of subcellular localization suggested that MITOSTATIN protein is localized at the mitochondrial level, we analysed MITOSTATIN effect on normal mitochondrial morphology. Mitochondrial shape results from the balance between fusion and fission, regulated by a family of 'mitochondria-shaping' proteins impinging on both sides of the equilibrium. Core components in mammals include the profusion proteins optic atrophy 1, mitofusins 1 and 2; and the profission ones Fis1 and dynamin-related protein 1 (Drp1) (Cereghetti and Scorrano, 2006) . We wished to verify if high levels of MITOSTATIN were associated with changes in normal mitochondrial morphology. To this end we expressed a mitostatin-V5 fusion protein together with the fluorescent protein dsRED targeted to the mitochondrial matrix (mt-dsRED) (Dimmer et al., 2008) and acquired confocal images of the mitochondrial reticulum in HeLa cells (Figures 3a-d) . The high levels of MITOSTATIN induced marked changes in mitochondrial morphology, including fragmentation of the highly branched network of HeLa cells and clumping of the fragmented organelles in the perinuclear region. As mitochondrial fragmentation can depend on the activation of the core fission machinery, we tested if a dominant negative mutant of Drp1 could interfere with the observed changes. The dominant negative Drp1 K38A (Smirnova et al., 1998) further elongated the mitochondrial network of HeLa cells and it blocked fragmentation induced by MITOSTATIN, as further confirmed by a morphometric analysis ( Figure 3e ). However, Drp1 K38A had no effect on perinuclear clusterization of mitochondria observed in cells expressing high levels of MITOSTATIN, suggesting that the two observed phenotypes can be functionally dissected. Of note, as these experiments were carried in the presence of the broad caspase inhibitor zVAD-fmk, it is unlikely that the observed changes reflect the activation by MITOSTATIN of the apoptotic cascade, often associated with mitochondrial fragmentation and clustering. In conclusion, fragmentation induced by MITOSTATIN depends on the core mitochondrial fission machinery, while it can induce perinuclear clustering of the organelle that occurs when fission is blocked.
To further investigate MITOSTATIN's relationship with mitochondria, we analysed wild-type PC3 prostate carcinoma-derived cells and PC3 MITOSTATIN-overexpressing clones (PC3 B2) by transmission electron microscopy. Ultrastructural analysis of MITOSTATINoverexpressing PC3 cells revealed that the mitochondria were often round and showed abnormal christae in contrast to the wild-type cells (Figure 4a ). In addition, mitochondria were often swollen and lost some of their christae and matrix material (Figures 4b and c) .
De novo expression of MITOSTATIN inhibits cell growth We hypothesized that MITOSTATIN could be linked to growth control insofar as it was a decorin-induced gene. Therefore, we utilized the MITOSTATIN-GFP constructs described above to test their biological activity in transformed cells. MITOSTATIN expression significantly affected HeLa colony formation, with a drastic reduction (65%) in the number and size of colonies as compared to vector-transfect controls (Figure 5a To further investigate the MITOSTATIN effects on tumor cell growth, we transfected PC3, LNCaP and 5637 cells with a MITOSTATIN-V5 fusion expression construct, and PC3 and DU145 cells with an antisense cDNA construct. Moreover, we placed MITOSTATIN in a self-inactivating retroviral vector under the control of an inducible Drosophila HSP70 promoter, which we used to transfect DU145 cells. We obtained five clones stably overexpressing MITOSTATIN and two clones which showed a decreased level of endogenous MITOS-TATIN (Figures 6a and b) . Clones showed different levels of the protein overexpression: in PC3 cells, PC3 B2 had a 2.0-fold increase over parental cells; DU145-MITOSTATIN showed a 4.2-fold increase; in LNCaP clones, LNCaP B1A, LNCaP B3A and LNCaP A3A had a 1.6-, 2.1-and 2.6-fold increase, respectively; 5637 B3 MITOSTATIN expression was 2.9 times over the parental cells expression.
As observed in transiently transfected clones, MI-TOSTATIN overexpressing clones showed a statistically significant reduction in cell number when compared with control vector and parental cells after 72 h (Figure 6c , n ¼ 3). Antisense clones PC3 M2 and DU145 M2 did not show a statistically significant growth increase in comparison to control cells (P ¼ NS, n ¼ 3).
A link between MITOSTATIN, Hsp27 expression and apoptosis Next, we determined whether MITOSTATIN would affect apoptosis. To this end, we treated various tumor cell lines with staurosporine (1 mM for 4 h), an established inducer of apoptosis (Mehlen et al., 1996) . Because several mitogen-activated protein kinases are involved in the control of the apoptotic process, we tested the activation of several proteins in the Akt and Jnk kinase pathways after induction of apoptosis by staurosporine treatment (data not shown). We discovered that the phosphorylation of Hsp27 at Ser 82 was specifically and uniquely inhibited by MITOSTATIN overexpression (Figure 7c ). Moreover, Hsp27 levels were inversely proportional to the levels of MITOSTA-TIN expression in prostate cancer cell lines (Figures 6b  and 7c) . Remarkably, Hsp27 decreased in LNCaP B1A, B3A and A3A MITOSTATIN overexpressing clones, and its level was higher than in the parental cells when MITOSTATIN expression was abrogated with antisense mRNA in clones PC3 M2 and DU145 M2 (Figure 6b) . In all cases, the MITOSTATIN-overexpressing cells showed a significant increase in apoptotic rate as compared to the low expressors (Figure 7a was also observed after treatments with H 2 O 2 , tumor necrosis factor-a and actinomycin D, three established inducers of apoptosis, in LNCaP and PC3 cell lines (data not showed). Collectively, our findings indicate that MITOSTATIN is involved in facilitating cancer cells death upon apoptotic stimuli.
MITOSTATIN is mutated in various transformed cell lines and its expression can be lost in tumor samples
To determine whether MITOSTATIN is mutated or lost in malignant human tumors, we performed a systematic analysis of cancer-derived cell lines and solid tumors using reverse transcription-PCR. MITOSTATIN mRNA was absent in B6% of the cancer samples (one vulva, two colon and three prostate cancers; 4.2% including the cancer cell lines). Also in the three prostate samples, we studied the normal counterpart in which the gene was normally expressed (Figure 8a ). Four point mutations were detected (Supplementary Figure S8) . In the gastric carcinoma-derived RF48 cell line, T345 in exon 2 was substituted in heterozygosity by a C, changing the amino acid from a serine to a proline (S44P). In the prostate-derived LNCaP cell line, C 184 in exon 9 was substituted in heterozygosity by a T, without amino acid changes (A323A). In the pancreatic carcinoma-derived SU86 cell line, G 890 in exon 6 was substituted in heterozygosity by an A, without changing the glutamic acid (E225E). In the CAPAN1 pancreatic carcinoma-derived cells, C 492 in exon 3 was homozygously mutated to A, changing the amino acid from glutamic acid to lysine (E93K). Notably, all these mutations affected amino-acid residues that are highly conserved in evolution (Figure 1c and Supplementary Figure S8 ). In immunofluorence confocal analysis, MITOSTATIN still showed a punctuate pattern of distribution and colocalized within mitochondria in LNCaP (Supplementary Figure S5) , CAPAN and Su86.
Reduced MITOSTATIN expression in advanced bladder and breast carcinomas To further confirm our hypothesis on the tumor suppressive nature of MITOSTATIN, we evaluated its expression in a series of bladder and breast cancers by immunohistochemistry. In normal samples, high MI-TOSTATIN levels were detected in normal urothelial and breast epithelial cells (Figures 8b and c , Supplementary Figure S9 ). Also, as expected from the RNA analysis (Figure 1 ), MITOSTATIN protein was readily detected in smooth muscle and endothelial cells (Figure 8b ). MITOSTATIN was mainly localized into the cytoplasm, in agreement with the mitochondrial nature detected by transient expression. Interestingly, in normal mammary glands a strong MITOSTATIN signal was detected in both cytoplasm and cell membrane. In contrast, 22% (10 of 45) of bladder cancers did not show any MITOSTATIN expression. Univariate analysis revealed a decreased MITOSTATIN immunohistochemical score associated with advanced tumor stage (P ¼ 0.003) (Figure 8c ) and higher pT (P ¼ 0.003). By multivariate analysis, the same variables were independently associated with MITOSTATIN immunohistochemical levels (stage P ¼ 0.005; pT P ¼ 0.004).
Approximately 23% (11 of 48) of the breast tumors did not express MITOSTATIN. In the univariate analysis, a decreased MITOSTATIN immunohistochemical score correlated to advanced tumor stage (P ¼ 0.047) ( Figure 8c ), and higher pT (P ¼ 0.027). In breast tumors, lower MITOSTATIN immunohistochemical expression was also associated, although not with statistical significance, with presence of lymph node metastases (P ¼ 0.053). There was no statistically significant association between MITOSTATIN expression and estrogen receptor and progesterone receptor status, histologic and nuclear grade, and tumor histotype (data not shown). No other clinical-pathological parameters resulted independently associated with MITOSTATIN expression in breast cancers in the multivariate analysis.
Discussion
Previous reports of allelic loss at chromosome 12q24 in solid tumors have identified frequencies ranging from 25 to 55% depending on marker sets used for LOH studies (Field et al., 1995; Shiseki et al., 1996; Schmutte et al., 1997; Tirkkonen et al., 1997; Jiang et al., 1998; Kimura et al., 1998; Koo et al., 1999; Rijken et al., 1999; Sattler et al., 1999; Aubele et al., 2000) . Interestingly, a restriction fragment length polymorphism study showed that deletions at 12q24 were more frequent in brain metastases (68% of LOH) of lung cancers than in stage I lung tumors (29-33% of LOH). In accordance with this report, a comparative genomic hybridization analysis on two microdissected breast carcinomas showed amplification of the central portion of chromosome 12 in the primary tumors and LOH at 12q24 in one metastatic lymph-node (Aubele et al., 1999) . We have previously suggested that thymine-DNA glycosylase (TDG), an enzyme initiating T:G mismatch repair by specifically excising T from those mismatches through a glysosylase mechanism in C-T transitions, may be a good tumor suppressor candidate for 12q24 deletions. To test our hypothesis, we first characterized the structure of the TDG gene and selected 10 out of 24 (42%) gastric carcinomas with LOH at the TDG locus. Nevertheless, although gastric cancer presents a high percentage of C-T transitions, we found no mutations within the coding sequence of the remaining TDG allele in the gastric samples that displayed LOH (Schmutte et al., 1997) . According to these results, we suggested that a gene different than TDG is the target of 12q24 deletions. In this study, we describe the identification and functional characterization of a novel putative tumor suppressor gene, MITOSTATIN, at 12q24.1 and show that MITOSTATIN has many of the hallmarks of a typical tumor suppressor gene. First, we show that MITOSTATIN is expressed, although at different levels, in all the human tissues we tested and that it colocalizes to the mitochondria, affecting mitochondria morphology and ultrastructural organization. Second, we show that MITOSTATIN significantly inhibits colony formation and evokes a dramatic reduction in the rate of DNA synthesis in various transformed cell lines. Third, MITOSTATIN overexpression is proapoptotic. Fourth, there is a direct correlation between the amount of intracellular MI-TOSTATIN protein and its biological effects: all MITOSTATIN-overexpressing cells show a lower growth rate, whereas cells overexpressing an antisense MITOSTATIN mRNA grow at a slight higher rate than parental cells.
A previous report (Nishizawa et al., 2005) indicated that MITOSTATIN is a cytoplasmic protein that colocalizes with keratin filaments and was therefore named trichoplein. However, although our findings did not exclude the interaction with keratins, they clearly show that MITOSTATIN associates with mitochondria even if it should be stressed that the association is not complete, the localization of the protein is on the outer membrane and that other unidentified intracellular structures are stained by anti-MITOSTATIN antibodies. Moreover, fusion to GFP of different fragments of MITOSTATIN showed that the first 111 amino acids are sufficient for a punctuate distribution that partially overlaps with mitochondria (VA and LS, unpublished data). The colocalization of MITOSTATIN with mitochondria (here) as well as with keratin filaments (Nishizawa et al., 2005) could rise the hypothesis that this protein regulates interaction of the organelle with the intermediate filaments, a process which impacts on movement and subcellular localization of the organelle (Anesti and Scorrano, 2006) . In fact, high levels of MITOSTATIN are associated with changes in the shape of the mitochondrial network, with a remarkable fragmentation and perinuclear clustering. Although the former depends on the activation of the core fission machinery, the latter occurs independently of it, as substantiated by the lack of inhibition by a dominant negative Drp1. The clusterization phenotype is typical of apoptotic cells, as observed in the late nineties in tumor necrosis factora-treated fibroblasts (De Vos et al., 1998) , as well as of cells overexpressing hFis1, the mitochondrial receptor for Drp1 (Frieden et al., 2004) . We could rule out not only that in our case it depended on Drp1, but also that it was an epiphenomenon of the proapoptotic action of MITOSTATIN, given the lack of inhibition by the caspase inhibitor zVAD-fmk. It is possible that the perinuclear clusterization reflects the hijack of mitochondria from microtubules to intermediate filaments, which MITOSTATIN can bind to (Nishizawa et al., 2005) .
The mitochondrial localization would also explain its potential involvement in apoptosis. Mitochondria are central organelles in the regulation of apoptosis, mainly by amplifying death signals by the release of cytochrome c and other protein cofactors from the inter-membrane space to the cytosol, where they activate effector caspases. The mechanisms by which increased expression of MITOSTATIN facilitates apoptosis remain to be resolved, but it is conceivable that this occurs through a facilitator effect on the mitochondrial pathway of apoptosis.
In this study, we discover a link between MITOSTA-TIN expression and Hsp27 phosphorylation. Hsp27 is a heat-shock protein and in quiescent cells exists predominantly as a large oligomeric unit of B800 kDa. During stress, the level of Hsp27 and the amount of phosphorylation on Ser 15, 78 and 82 increases, resulting in a shift in Hsp27 from an oligomeric unit to tetrameric and dimeric units (Bruey et al., 2000) . Hsp27 has cytoprotective effects during cellular stress and operates as a molecular chaperone inhibiting protein unfolding. Hsp27 also directly interferes with caspase activation, modulates oxidative stress and regulates the cytoskeleton scaffolding (Parcellier et al., 2003) . Higher levels of Hsp27 have been correlated with an increased metastatic potential of tumor cells in vitro and in vivo as well as an enhanced resistance to therapy (Kamada et al., 2007) . Hsp27 has been frequently detected overexpressed in human cancer (Love and King, 1994; Ehrenfried et al., 1995; Langdon et al., 1995; Takashi et al., 1998; Cornford et al., 2000; Lebret et al., 2003) . Specifically in prostate cancer, elevated Hsp27 expression has been linked to hormone resistance and poor outcome (Rocchi et al., 2004 (Rocchi et al., , 2005 . Thus, MITOSTATIN-evoked effects on Hsp27 phosphorylation might be directly linked to MITOSTATIN ability to inhibit cell growth and be proapoptotic during cell stress.
The loss of tumor suppressor gene regulatory function represents an important step in malignant progression (Hanahan and Weinberg, 2000) . Mutations of tumor suppressor genes are considered recessive, and both copies of these genes must be inactivated before the cell is at risk of transformation, the so-called 'two hit' hypothesis (Knudson, 2000) . The heterozygous situation, in which only one allele is not functioning, may cause a reduced action of the gene (haploinsufficiency) and favors the development of the neoplastic phenotype. Therefore, after we determined that MITOSTATIN is localized in a chromosomal region deleted in cancer and that its expression is induced by decorin, a cancer-cell growth inhibitor (Iozzo, 1998) , we performed a mutational analysis in cell lines and primary human tumors of different origin. Approximately 6% of the cancer samples analysed show homozygous deletions of the MITOSTATIN gene. In three primary human prostate cancers, we showed that the MITOSTATIN mRNA was normally expressed in the normal adjacent glands. Three of the four point mutations present in cancer cell lines (RF48 gastric carcinoma-derived cell line, prostate cancer LNCaP cell line and pancreatic carcinoma-derived SU86 cell line) were detected in one of the two MITOSTATIN alleles together with the normal allele. MITOSTATIN was homozygously mutated in the CAPAN1 pancreatic carcinoma-derived cells. The low incidence of MITOS-TATIN mutations suggests that other molecular mechanisms are responsible for the loss of expression of MITOSTATIN observed in primary tumors. The presence of mutations in only one of the two alleles also suggests that MITOSTATIN could also be a haploinsufficient tumor suppressor.
Several reports have suggested that 12q24 contains a tumor suppressor gene involved in multiple tumor types (Field et al., 1995; Shiseki et al., 1996; Schmutte et al., 1997; Tirkkonen et al., 1997; Jiang et al., 1998; Kimura et al., 1998; Koo et al., 1999; Rijken et al., 1999; Sattler et al., 1999; Aubele et al., 2000) . We mapped the MITOSTATIN gene to this region and showed a loss of MITOSTATIN RNA expression in several carcinomas. Although, the status of DNA and RNA is important, the actual determinant of a gene function is its protein expression. Using immunohistochemistry experiments, we showed that MITOSTATIN protein is absent or greatly reduced in 22% of human bladder cancers and 23% of breast adenocarcinomas. Loss of MITOSTA-TIN expression correlates with advanced disease in both types of cancer. Furthermore, it was associated with lymph-node metastases in breast cancer. These in vivo data represent an additional evidence of the possible tumor suppressor function of MITOSTATIN.
In conclusion, we have identified and functionally characterized MITOSTATIN, a novel putative tumor suppressor gene localized to the mitochondria. We further provide the first evidence that loss of MITOS-TATIN protein expression may play a role in human tumorigenesis. Thus, loss of function of MITOSTATIN may interrupt the inhibitory circuit, possibly regulated by extracellular components, such as decorin, facilitating the growth and spread of neoplastic cells.
Our findings support the hypothesis that MITOSTA-TIN behaves as a classical tumor suppressor in solid tumors. Furthermore, we demonstrate, for the first time, that MITOSTATIN is implicated in the control of cell growth and apoptosis and that MITOSTATIN protein is significantly decreased or absent in advanced bladder and breast cancers. It remains to be determined how MITOSTATIN functions in mitochondrial homeostasis as well as how a mitochondrial protein acts as tumor suppressor. Additional functional studies are needed to clarify the role of this protein in neoplastic transformation, and the mechanisms of MITOSTATIN inactivation.
Materials and methods

Materials
Additional details of materials are provided in Supplementary Information.
Tissue samples
A total of 102 (26 matched normal and tumor tissues) deidentified frozen primary tumors were collected from 1994 to 2000 from archives of the Pathology Department of Thomas Jefferson University. Samples studied included 31 bladder, 23 colon-rectum, 20 prostate, 13 ovary, 13 vulva and 2 cervical cancers. All samples were obtained from patients who gave informed consent to use excess pathological specimens for research purposes. The AccuMax Array-A215 (ISU ABXIS Co., Seoul, South Korea) including ninety-four 0.6-mm bladder cancer cores was utilized for the immunohistochemistry. Forty-eight invasive breast carcinomas (41 ductal and 7 lobular) were selected from the Pathology Tissue Bank of Thomas Jefferson University and used to develop a tissue microarray based upon the appropriate IRB-approved protocol. Adjacent normal breast from four diseased patients was also included.
Cell proliferation, colony formation assays and subcellular fractionation Cells were plated in triplicate in a six-well tissue culture plate. Proliferation was assessed by counting the cells daily for 4 days, and the mean values of three independent experiments were analysed. Colony forming assay was performed on cells plated at a density of 400 cells per 100 mm dish. On day 15, cells were fixed with phosphate-buffered saline-3.7% formaldehyde and stained with crystal violet for colony counting. Separation of crude organelle fractions was performed on cell using the differential centrifugation methods (Bourgeron et al., 1992; Peruzzi et al., 1999) with minor modifications.
Generation of MITOSTATIN polyclonal antibody and immunological analyses
The anti-MITOSTATIN antibody was raised in rabbit against glutathione 6HIS-fusion MITOSTATIN protein corresponding to nucleotides 816-1712, which was expressed in Escherichia coli and purified with a fusion tag column. Protein extraction and immunoblot analyses were carried out as described previously (Vecchione et al., 2002) . Anti-MITOS-TATIN (1:1000), anti-actin (1:10 000; Sigma, St. Louis, MO, USA), anti-FLAG (1:1000; Sigma), anti-cytochrome c (1:1000; Cell Signaling, Beverly, MA, USA), anti-caspase-3 (1:1000; BD Pharmingen Inc., San Diego, CA, USA), anti-PARP (1:1000; BD Pharmingen Inc.), anti-HSP27 (1:1000; Cell Signaling), anti-p38 MAP kinase (1:1000) and the phosphorylated anti-phospho-HSP27 ser82 (1:1000), anti-phospho-HSP27 ser78 (1:1000) and anti-phospho-p38 MAPK thr180/ tyr182 (1:1000) were used as primary antibodies. Immunofluorescence experiments were carried out on fixed cells as described before (Monami et al., 2006) .
Immunohistochemistry
In this study, we used the immunohistochemistry procedure described previously (Vecchione et al., 2002) with minor modifications. Sections were immunostained overnight at room temperature with a 1:100 dilution of the anti-MITOS-TATIN antibody. The primary antibody was omitted and replaced with pre-immune serum in the negative control. All sections were examined independently by two investigators (RB, JPP), and complete agreement was reached for MITOS-TATIN positivity and negativity. Positive staining of anti-MITOSTATIN antibody was semiquantified with a four-tier system: þ þ þ , 67-100% MITOSTATIN-positive cells; þ þ , 34-66% MITOSTATIN-positive cells; þ , 5-33% MITOSTATIN-positive cells; and 0, the tumors in which >95% of cells did not express MITOSTATIN.
Statistical analysis
Statistical analysis was carried out with SigmaStat for Windows version 3.10 (Systat Software). All values were expressed as mean ± s.e. Differences between means were evaluated with double-sided Z-test. The w 2 test was used to examine the categorical variables and the association between MITOSTATIN immunohistochemical expression levels and other clinicopathological variables in univariate analysis. To identify variables independently associated with MITOSTATIN immunohistochemical levels, backward selection multivariate analysis was performed using the logistic regression model. Differences were considered statistically significant at Po0.05.
Abbreviations
GFP, green fluorescent protein; LOH, loss of heterozygosity.
